A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Eribulin (Primary) ; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 01 Sep 2017 Results assessing the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer, were published in the Annals of Oncology.
- 10 Jun 2017 Biomarkers information updated
- 22 Jun 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History